Cassilândia, Brazil
Cassilândia, Brazil

Time filter

Source Type

News Article | May 15, 2017
Site: globenewswire.com

Mechelen, Belgium; 15 May 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces the acceptance of seven abstracts from several clinical and pre-clinical studies with the investigational agent filgotinib in rheumatoid and psoriatic arthritis, by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June. Following is a list of accepted abstracts: "Long term safety and efficacy of filgotinib in a Phase 2b open label extension study in patients with rheumatoid arthritis: results up to 144 weeks" "The JAK1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients" "Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients" "The JAK1-selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis" "The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model" "Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate" "Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies" All abstracts are available on the website of the EULAR 2017 Congress. Filgotinib is an investigational drug and its efficacy and safety have not been established. For information about the studies with filgotinib: www.clinicaltrials.gov For more information about filgotinib: www.glpg.com/filgotinib About filgotinib Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Following the Phase 2 DARWIN and FITZROY results, filgotinib is currently being investigated in the FINCH Phase 3 program in rheumatoid arthritis, the DIVERSITY Phase 3 program in Crohn's disease and in the SELECTION Phase 2b/3 study in ulcerative colitis. Furthermore, filgotinib is being studied in Phase 2 studies for small bowel and fistulizing Crohn's disease, cutaneous lupus erythematosus (CLE), Sjögren's syndrome, ankylosing spondylitis (TORTUGA), and psoriatic arthritis (EQUATOR). About EULAR The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems. About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 530 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com. Forward-Looking Statements This release may contain forward-looking statements, including statements regarding Galapagos' strategic ambitions, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.


News Article | May 15, 2017
Site: globenewswire.com

Mechelen, België; 15 mei 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) maakt bekend dat het Annual European Congress of Rheumatology, georganiseerd door de European League Against Rheumatism (EULAR), zeven abstracts over klinische en preklinische studies met filgotinib in reuma en psoriatische artritis heeft geaccepteerd. EULAR vindt plaats van 14 tot 17 juni in Madrid. Hier volgt een lijst van geaccepteerde abstracts: "Long term safety and efficacy of filgotinib in a Phase 2b open label extension study in patients with rheumatoid arthritis: results up to 144 weeks" "The JAK1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients" "Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients" "The JAK1-selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis" "The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model" "Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate" "Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two Phase 2b studies" Filgotinib is een medicijn in ontwikkeling; de veiligheid en werkzaamheid is nog niet definitief vastgesteld. Meer informatie over de studies met filgotinib: www.clinicaltrials.gov Meer informatie over filgotinib: www.glpg.com/filgotinib Over filgotinib Galapagos en Gilead hebben een wereldwijde samenwerkingsovereenkomst voor de ontwikkeling en commercialisatie van filgotinib in ontstekingsziekten. Voortbouwend op de resultaten van de Fase 2 studies DARWIN en FITZROY, wordt filgotinib nu onderzocht in de FINCH Fase 3 studie in reumatoide artritis, de DIVERSITY Fase 3 studie in de ziekte van Crohn en in de SELECTION Fase 2b/3 studie in colitis ulcerosa. Daarnaast wordt filgotinib ook onderzocht in Fase 2 studies in de ziekte van Crohn in de dunne darm en bij fistelvorming, lupus erythematosus (CLE), het syndroom van Sjögren, de ziekte van Bechterew (TORTUGA) en psoriatische artritis (EQUATOR). Over EULAR De European League Against Rheumatism (EULAR) is de organisatie die de reumatologische verenigingen van patiënten, gezondheidsprofessionals en wetenschappers van alle Europese landen vertegenwoordigt. EULAR streeft ernaar onderzoek, preventie, behandeling en rehabilitatie van reumatische ziekten te stimuleren, promoten en ondersteunen. In lijn met UEMS, definieert EULAR reuma inclusief reumatische aandoeningen van bindweefsel, het bewegings- en het musculoskeletale apparaat. Over Galapagos Galapagos (Euronext & NASDAQ: GLPG) is een biotechnologiebedrijf in de klinische fase, gespecialiseerd in het ontdekken en ontwikkelen van geneesmiddelen met nieuwe werkingsmechanismen. Onze pijplijn bestaat uit Fase 3, 2, Fase 1, preklinische studies en onderzoeksprogramma's in cystic fibrosis, fibrose, artrose, ontstekings- en andere ziekten. Wij hebben filgotinib ontdekt en ontwikkeld: in samenwerking met Gilead streven we ernaar om deze selectieve JAK1-remmer in ontstekingsziekten wereldwijd voor patiënten beschikbaar te maken. We richten ons op het ontwikkelen en het commercialiseren van nieuwe medicijnen die het leven van mensen verbeteren. De Galapagos groep, met inbegrip van fee-for-service dochter Fidelta, heeft ongeveer 530 medewerkers in het hoofdkantoor in Mechelen, België en in de vestigingen in Nederland, Frankrijk en Kroatië. Meer informatie op www.glpg.com. Contact Toekomstgerichte verklaringen Dit bericht kan toekomstgerichte verklaringen bevatten, waaronder (zonder beperking) verklaringen omtrent de strategische ambities van Galapagos, de verwachte timing van klinische studies met filgotinib, en de vooruitgang en resultaten van dergelijke studies. Galapagos waarschuwt de lezer dat toekomstgerichte verklaringen geen garanties inhouden voor toekomstige prestaties. Toekomstgerichte verklaringen kunnen gekende en ongekende risico's en onzekerheden en andere factoren inhouden die ertoe zouden kunnen leiden dat de werkelijke resultaten, financiële toestand en liquiditeitspositie, prestaties of realisaties van Galapagos, of de ontwikkeling van de sector waarin zij actief is, beduidend verschillen van historische resultaten of van toekomstige resultaten, financiële toestand, prestaties of realisaties die door dergelijke toekomstgerichte verklaringen expliciet of impliciet worden uitgedrukt. Bovendien, zelfs indien Galapagos' resultaten, financiële toestand en liquiditeitspositie, prestaties of realisaties van Galapagos, of de ontwikkeling van de sector waarin zij actief is wel overeenstemmen met deze toekomstgerichte verklaringen, kunnen deze toekomstgerichte verklaringen nog steeds geen voorspellende waarde hebben voor resultaten en ontwikkelingen in de toekomst. Onder andere volgende factoren zouden aanleiding kunnen geven tot dergelijke verschillen: de inherente onzekerheden die gepaard gaan met concurrentiële ontwikkelingen, klinische studies en activiteiten op het gebied van productontwikkeling en goedkeuringsvereisten van toezichthouders (met inbegrip van, maar niet beperkt tot, het feit dat data die voortkomen uit de klinische onderzoeksprogramma's, de registratie of verdere ontwikkeling van filgotinib niet zouden ondersteunen omwille van veiligheid, werkzaamheid of andere redenen), Galapagos' afhankelijkheid van samenwerkingen met derden (inclusief Gilead, haar samenwerkingspartner voor filgotinib), en de inschatting van het commercieel potentieel van filgotinib. Een meer uitgebreide lijst en omschrijving van deze risico's, onzekerheden, en andere risico's kan worden gevonden in de documenten en verslagen die Galapagos indient bij de U.S. Securities and Exchange Commission (SEC), inclusief Galapagos' meest recente jaarverslag op formulier 20-F ingediend bij de SEC en andere documenten en rapporten ingediend door Galapagos bij de SEC. Gelet op deze onzekerheden wordt de lezer aangeraden om geen al te groot vertrouwen te hechten aan deze toekomstgerichte verklaringen. Deze toekomstgerichte verklaringen gelden slechts op de datum van publicatie van dit document. Galapagos wijst uitdrukkelijk elke verplichting af om toekomstgerichte verklaringen in dit document aan te passen aan enige wijziging van haar verwachtingen aangaande deze toekomstgerichte verklaringen of van enige wijziging in de gebeurtenissen, voorwaarden en omstandigheden waarop dergelijke verklaringen zijn gebaseerd of die een impact kunnen hebben op de waarschijnlijkheid dat de werkelijke resultaten zullen verschillen van degene die in de toekomstgerichte verklaringen worden vermeld, tenzij dit specifiek wettelijk of reglementair verplicht is.


News Article | May 15, 2017
Site: globenewswire.com

Mechelen, België; 15 mei 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) maakt bekend dat het Annual European Congress of Rheumatology, georganiseerd door de European League Against Rheumatism (EULAR), zeven abstracts over klinische en preklinische studies met filgotinib in reuma en psoriatische artritis heeft geaccepteerd. EULAR vindt plaats van 14 tot 17 juni in Madrid. Hier volgt een lijst van geaccepteerde abstracts: "Long term safety and efficacy of filgotinib in a Phase 2b open label extension study in patients with rheumatoid arthritis: results up to 144 weeks" "The JAK1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients" "Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients" "The JAK1-selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis" "The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model" "Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate" "Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two Phase 2b studies" Filgotinib is een medicijn in ontwikkeling; de veiligheid en werkzaamheid is nog niet definitief vastgesteld. Meer informatie over de studies met filgotinib: www.clinicaltrials.gov Meer informatie over filgotinib: www.glpg.com/filgotinib Over filgotinib Galapagos en Gilead hebben een wereldwijde samenwerkingsovereenkomst voor de ontwikkeling en commercialisatie van filgotinib in ontstekingsziekten. Voortbouwend op de resultaten van de Fase 2 studies DARWIN en FITZROY, wordt filgotinib nu onderzocht in de FINCH Fase 3 studie in reumatoide artritis, de DIVERSITY Fase 3 studie in de ziekte van Crohn en in de SELECTION Fase 2b/3 studie in colitis ulcerosa. Daarnaast wordt filgotinib ook onderzocht in Fase 2 studies in de ziekte van Crohn in de dunne darm en bij fistelvorming, lupus erythematosus (CLE), het syndroom van Sjögren, de ziekte van Bechterew (TORTUGA) en psoriatische artritis (EQUATOR). Over EULAR De European League Against Rheumatism (EULAR) is de organisatie die de reumatologische verenigingen van patiënten, gezondheidsprofessionals en wetenschappers van alle Europese landen vertegenwoordigt. EULAR streeft ernaar onderzoek, preventie, behandeling en rehabilitatie van reumatische ziekten te stimuleren, promoten en ondersteunen. In lijn met UEMS, definieert EULAR reuma inclusief reumatische aandoeningen van bindweefsel, het bewegings- en het musculoskeletale apparaat. Over Galapagos Galapagos (Euronext & NASDAQ: GLPG) is een biotechnologiebedrijf in de klinische fase, gespecialiseerd in het ontdekken en ontwikkelen van geneesmiddelen met nieuwe werkingsmechanismen. Onze pijplijn bestaat uit Fase 3, 2, Fase 1, preklinische studies en onderzoeksprogramma's in cystic fibrosis, fibrose, artrose, ontstekings- en andere ziekten. Wij hebben filgotinib ontdekt en ontwikkeld: in samenwerking met Gilead streven we ernaar om deze selectieve JAK1-remmer in ontstekingsziekten wereldwijd voor patiënten beschikbaar te maken. We richten ons op het ontwikkelen en het commercialiseren van nieuwe medicijnen die het leven van mensen verbeteren. De Galapagos groep, met inbegrip van fee-for-service dochter Fidelta, heeft ongeveer 530 medewerkers in het hoofdkantoor in Mechelen, België en in de vestigingen in Nederland, Frankrijk en Kroatië. Meer informatie op www.glpg.com. Contact Toekomstgerichte verklaringen Dit bericht kan toekomstgerichte verklaringen bevatten, waaronder (zonder beperking) verklaringen omtrent de strategische ambities van Galapagos, de verwachte timing van klinische studies met filgotinib, en de vooruitgang en resultaten van dergelijke studies. Galapagos waarschuwt de lezer dat toekomstgerichte verklaringen geen garanties inhouden voor toekomstige prestaties. Toekomstgerichte verklaringen kunnen gekende en ongekende risico's en onzekerheden en andere factoren inhouden die ertoe zouden kunnen leiden dat de werkelijke resultaten, financiële toestand en liquiditeitspositie, prestaties of realisaties van Galapagos, of de ontwikkeling van de sector waarin zij actief is, beduidend verschillen van historische resultaten of van toekomstige resultaten, financiële toestand, prestaties of realisaties die door dergelijke toekomstgerichte verklaringen expliciet of impliciet worden uitgedrukt. Bovendien, zelfs indien Galapagos' resultaten, financiële toestand en liquiditeitspositie, prestaties of realisaties van Galapagos, of de ontwikkeling van de sector waarin zij actief is wel overeenstemmen met deze toekomstgerichte verklaringen, kunnen deze toekomstgerichte verklaringen nog steeds geen voorspellende waarde hebben voor resultaten en ontwikkelingen in de toekomst. Onder andere volgende factoren zouden aanleiding kunnen geven tot dergelijke verschillen: de inherente onzekerheden die gepaard gaan met concurrentiële ontwikkelingen, klinische studies en activiteiten op het gebied van productontwikkeling en goedkeuringsvereisten van toezichthouders (met inbegrip van, maar niet beperkt tot, het feit dat data die voortkomen uit de klinische onderzoeksprogramma's, de registratie of verdere ontwikkeling van filgotinib niet zouden ondersteunen omwille van veiligheid, werkzaamheid of andere redenen), Galapagos' afhankelijkheid van samenwerkingen met derden (inclusief Gilead, haar samenwerkingspartner voor filgotinib), en de inschatting van het commercieel potentieel van filgotinib. Een meer uitgebreide lijst en omschrijving van deze risico's, onzekerheden, en andere risico's kan worden gevonden in de documenten en verslagen die Galapagos indient bij de U.S. Securities and Exchange Commission (SEC), inclusief Galapagos' meest recente jaarverslag op formulier 20-F ingediend bij de SEC en andere documenten en rapporten ingediend door Galapagos bij de SEC. Gelet op deze onzekerheden wordt de lezer aangeraden om geen al te groot vertrouwen te hechten aan deze toekomstgerichte verklaringen. Deze toekomstgerichte verklaringen gelden slechts op de datum van publicatie van dit document. Galapagos wijst uitdrukkelijk elke verplichting af om toekomstgerichte verklaringen in dit document aan te passen aan enige wijziging van haar verwachtingen aangaande deze toekomstgerichte verklaringen of van enige wijziging in de gebeurtenissen, voorwaarden en omstandigheden waarop dergelijke verklaringen zijn gebaseerd of die een impact kunnen hebben op de waarschijnlijkheid dat de werkelijke resultaten zullen verschillen van degene die in de toekomstgerichte verklaringen worden vermeld, tenzij dit specifiek wettelijk of reglementair verplicht is.


News Article | May 15, 2017
Site: globenewswire.com

Mechelen, Belgium; 15 May 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces the acceptance of seven abstracts from several clinical and pre-clinical studies with the investigational agent filgotinib in rheumatoid and psoriatic arthritis, by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June. Following is a list of accepted abstracts: "Long term safety and efficacy of filgotinib in a Phase 2b open label extension study in patients with rheumatoid arthritis: results up to 144 weeks" "The JAK1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients" "Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients" "The JAK1-selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis" "The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model" "Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate" "Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies" All abstracts are available on the website of the EULAR 2017 Congress. Filgotinib is an investigational drug and its efficacy and safety have not been established. For information about the studies with filgotinib: www.clinicaltrials.gov For more information about filgotinib: www.glpg.com/filgotinib About filgotinib Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Following the Phase 2 DARWIN and FITZROY results, filgotinib is currently being investigated in the FINCH Phase 3 program in rheumatoid arthritis, the DIVERSITY Phase 3 program in Crohn's disease and in the SELECTION Phase 2b/3 study in ulcerative colitis. Furthermore, filgotinib is being studied in Phase 2 studies for small bowel and fistulizing Crohn's disease, cutaneous lupus erythematosus (CLE), Sjögren's syndrome, ankylosing spondylitis (TORTUGA), and psoriatic arthritis (EQUATOR). About EULAR The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems. About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 530 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com. Forward-Looking Statements This release may contain forward-looking statements, including statements regarding Galapagos' strategic ambitions, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.


News Article | May 15, 2017
Site: globenewswire.com

Mechelen, België; 15 mei 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) maakt bekend dat het Annual European Congress of Rheumatology, georganiseerd door de European League Against Rheumatism (EULAR), zeven abstracts over klinische en preklinische studies met filgotinib in reuma en psoriatische artritis heeft geaccepteerd. EULAR vindt plaats van 14 tot 17 juni in Madrid. Hier volgt een lijst van geaccepteerde abstracts: "Long term safety and efficacy of filgotinib in a Phase 2b open label extension study in patients with rheumatoid arthritis: results up to 144 weeks" "The JAK1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients" "Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients" "The JAK1-selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis" "The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model" "Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate" "Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two Phase 2b studies" Filgotinib is een medicijn in ontwikkeling; de veiligheid en werkzaamheid is nog niet definitief vastgesteld. Meer informatie over de studies met filgotinib: www.clinicaltrials.gov Meer informatie over filgotinib: www.glpg.com/filgotinib Over filgotinib Galapagos en Gilead hebben een wereldwijde samenwerkingsovereenkomst voor de ontwikkeling en commercialisatie van filgotinib in ontstekingsziekten. Voortbouwend op de resultaten van de Fase 2 studies DARWIN en FITZROY, wordt filgotinib nu onderzocht in de FINCH Fase 3 studie in reumatoide artritis, de DIVERSITY Fase 3 studie in de ziekte van Crohn en in de SELECTION Fase 2b/3 studie in colitis ulcerosa. Daarnaast wordt filgotinib ook onderzocht in Fase 2 studies in de ziekte van Crohn in de dunne darm en bij fistelvorming, lupus erythematosus (CLE), het syndroom van Sjögren, de ziekte van Bechterew (TORTUGA) en psoriatische artritis (EQUATOR). Over EULAR De European League Against Rheumatism (EULAR) is de organisatie die de reumatologische verenigingen van patiënten, gezondheidsprofessionals en wetenschappers van alle Europese landen vertegenwoordigt. EULAR streeft ernaar onderzoek, preventie, behandeling en rehabilitatie van reumatische ziekten te stimuleren, promoten en ondersteunen. In lijn met UEMS, definieert EULAR reuma inclusief reumatische aandoeningen van bindweefsel, het bewegings- en het musculoskeletale apparaat. Over Galapagos Galapagos (Euronext & NASDAQ: GLPG) is een biotechnologiebedrijf in de klinische fase, gespecialiseerd in het ontdekken en ontwikkelen van geneesmiddelen met nieuwe werkingsmechanismen. Onze pijplijn bestaat uit Fase 3, 2, Fase 1, preklinische studies en onderzoeksprogramma's in cystic fibrosis, fibrose, artrose, ontstekings- en andere ziekten. Wij hebben filgotinib ontdekt en ontwikkeld: in samenwerking met Gilead streven we ernaar om deze selectieve JAK1-remmer in ontstekingsziekten wereldwijd voor patiënten beschikbaar te maken. We richten ons op het ontwikkelen en het commercialiseren van nieuwe medicijnen die het leven van mensen verbeteren. De Galapagos groep, met inbegrip van fee-for-service dochter Fidelta, heeft ongeveer 530 medewerkers in het hoofdkantoor in Mechelen, België en in de vestigingen in Nederland, Frankrijk en Kroatië. Meer informatie op www.glpg.com. Contact Toekomstgerichte verklaringen Dit bericht kan toekomstgerichte verklaringen bevatten, waaronder (zonder beperking) verklaringen omtrent de strategische ambities van Galapagos, de verwachte timing van klinische studies met filgotinib, en de vooruitgang en resultaten van dergelijke studies. Galapagos waarschuwt de lezer dat toekomstgerichte verklaringen geen garanties inhouden voor toekomstige prestaties. Toekomstgerichte verklaringen kunnen gekende en ongekende risico's en onzekerheden en andere factoren inhouden die ertoe zouden kunnen leiden dat de werkelijke resultaten, financiële toestand en liquiditeitspositie, prestaties of realisaties van Galapagos, of de ontwikkeling van de sector waarin zij actief is, beduidend verschillen van historische resultaten of van toekomstige resultaten, financiële toestand, prestaties of realisaties die door dergelijke toekomstgerichte verklaringen expliciet of impliciet worden uitgedrukt. Bovendien, zelfs indien Galapagos' resultaten, financiële toestand en liquiditeitspositie, prestaties of realisaties van Galapagos, of de ontwikkeling van de sector waarin zij actief is wel overeenstemmen met deze toekomstgerichte verklaringen, kunnen deze toekomstgerichte verklaringen nog steeds geen voorspellende waarde hebben voor resultaten en ontwikkelingen in de toekomst. Onder andere volgende factoren zouden aanleiding kunnen geven tot dergelijke verschillen: de inherente onzekerheden die gepaard gaan met concurrentiële ontwikkelingen, klinische studies en activiteiten op het gebied van productontwikkeling en goedkeuringsvereisten van toezichthouders (met inbegrip van, maar niet beperkt tot, het feit dat data die voortkomen uit de klinische onderzoeksprogramma's, de registratie of verdere ontwikkeling van filgotinib niet zouden ondersteunen omwille van veiligheid, werkzaamheid of andere redenen), Galapagos' afhankelijkheid van samenwerkingen met derden (inclusief Gilead, haar samenwerkingspartner voor filgotinib), en de inschatting van het commercieel potentieel van filgotinib. Een meer uitgebreide lijst en omschrijving van deze risico's, onzekerheden, en andere risico's kan worden gevonden in de documenten en verslagen die Galapagos indient bij de U.S. Securities and Exchange Commission (SEC), inclusief Galapagos' meest recente jaarverslag op formulier 20-F ingediend bij de SEC en andere documenten en rapporten ingediend door Galapagos bij de SEC. Gelet op deze onzekerheden wordt de lezer aangeraden om geen al te groot vertrouwen te hechten aan deze toekomstgerichte verklaringen. Deze toekomstgerichte verklaringen gelden slechts op de datum van publicatie van dit document. Galapagos wijst uitdrukkelijk elke verplichting af om toekomstgerichte verklaringen in dit document aan te passen aan enige wijziging van haar verwachtingen aangaande deze toekomstgerichte verklaringen of van enige wijziging in de gebeurtenissen, voorwaarden en omstandigheden waarop dergelijke verklaringen zijn gebaseerd of die een impact kunnen hebben op de waarschijnlijkheid dat de werkelijke resultaten zullen verschillen van degene die in de toekomstgerichte verklaringen worden vermeld, tenzij dit specifiek wettelijk of reglementair verplicht is.


News Article | May 15, 2017
Site: globenewswire.com

Mechelen, Belgium; 15 May 2017, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces the acceptance of seven abstracts from several clinical and pre-clinical studies with the investigational agent filgotinib in rheumatoid and psoriatic arthritis, by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June. Following is a list of accepted abstracts: "Long term safety and efficacy of filgotinib in a Phase 2b open label extension study in patients with rheumatoid arthritis: results up to 144 weeks" "The JAK1-selective inhibitor filgotinib reduces multiple markers of inflammation linked to various pathologic cell types and processes in rheumatoid arthritis patients" "Monotherapy with the JAK1-selective inhibitor filgotinib displays an anti-inflammatory biomarker profile in rheumatoid arthritis patients" "The JAK1-selective inhibitor filgotinib regulates both enthesis and colon inflammation in a mouse model of psoriatic arthritis" "The JAK1-selective inhibitor filgotinib inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model" "Effects of the JAK1-selective inhibitor filgotinib on multibiomarker disease activity scores in patients with active rheumatoid arthritis and an inadequate response to methotrexate" "Effect of baseline serum CRP levels on clinical efficacy in rheumatoid arthritis patients treated with filgotinib: post-hoc analysis from two phase 2b studies" All abstracts are available on the website of the EULAR 2017 Congress. Filgotinib is an investigational drug and its efficacy and safety have not been established. For information about the studies with filgotinib: www.clinicaltrials.gov For more information about filgotinib: www.glpg.com/filgotinib About filgotinib Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. Following the Phase 2 DARWIN and FITZROY results, filgotinib is currently being investigated in the FINCH Phase 3 program in rheumatoid arthritis, the DIVERSITY Phase 3 program in Crohn's disease and in the SELECTION Phase 2b/3 study in ulcerative colitis. Furthermore, filgotinib is being studied in Phase 2 studies for small bowel and fistulizing Crohn's disease, cutaneous lupus erythematosus (CLE), Sjögren's syndrome, ankylosing spondylitis (TORTUGA), and psoriatic arthritis (EQUATOR). About EULAR The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems. About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 530 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com. Forward-Looking Statements This release may contain forward-looking statements, including statements regarding Galapagos' strategic ambitions, the anticipated timing of clinical studies with filgotinib and the progression and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.


Schiavo J.A.,State University of Mato Grosso do Sul | Pereira M.G.,Federal Rural University of Rio de Janeiro | de Miranda L.P.M.,São Paulo State University | Neto A.H.D.,UEMS | Fontana A.,Engenheiro Agronomo do INCRA
Revista Brasileira de Ciencia do Solo | Year: 2010

The Aquidauana geological formation consists of a set of up to 500 m thick sediments predominantly composed of sandstone with fine to medium grain size, interspersed with sandy conglomerates. In this environment, the topography is one of the main conditioning factors of the formation of different soil types in the landscape. The objective of this study was to characterize and classify soils developed from these sandstones. Four soils profiles along a representative toposequence of gentle slopes were sampled and studied. The profiles were located on the shoulder (P1), backslope (P2), footslope (P3) and toeslope (P4). The soil profiles were morphologically described and physical and chemical properties of their horizons evaluated. The sand fraction was predominant in all profiles (> 680 g kg-1), with textures ranging from sandy loam (P4) to clay sandy loam. The water pH values ranged from 4.2 to 6.5. The cation exchange capacity values ranged from 1.6 cmolc kg-1(in P4) to 10.3 cmolc kg-1 (in P2), with a predominance of hydrogen ions in P1 and P4, and calcium in profile P2 and P3. The P1 and P4 pedons were dystrophic, whereas in P2 and P3, a high base saturation status evidenced an eutrophic character. Except in P2, the profiles presented low activity clays. In all soil profiles the morphological, physical, chemical and mineralogical properties were conditioned by the parent material and relief, demonstrating the influence of these factors on the pedogenesis.


This study aimed to evaluate different proportions of organic compost and soil as a substrate for the guavira emergence and seedling formation under different protected environments, in the high Pantanal region of the state of Mato Grosso do Sul. The seeds were placed in polyethylene bags (15 × 25 centimeters) filled with four percentages of organic compost (0%, 20%, 80%, and 100% of total volume) mixed with soil. These substrates were tested in agro-nurseries covered with black screen and 50% thermo-reflecting shade cloths. The substrate with 20% soil and 80% organic compost and the black screen shade cloth promote the best performance in the seedling production.


Pereira M.G.,Federal Rural University of Rio de Janeiro | Schiavo J.A.,State University of Mato Grosso do Sul | Fontana A.,Embrapa Solos | Neto A.H.D.,UEMS | de Miranda L.P.M.,São Paulo State University
Revista Brasileira de Ciencia do Solo | Year: 2013

The soils in the Serra da Bodoquena, a mountain chain in the state of Mato Grosso do Sul, Brazil, have peculiar features that differ from other regions of the Cerrado-Pantanal biome. This study aims to characterize soils formed on limestone, based on the physical, chemical and mineralogical properties and organic matter. A toposequence on limestone was selected and profile pits were opened on the summit (P1), backslope (P2), footslope (P3) and toeslope (P4 and P5). The profiles were morphologically described and physical, chemical and mineralogical analyses were carried out in all horizons. According to the Brazilian System of Soil Classification (SiBCS), the studied soils were classified as: (P1) Organossolo Fólico Sáprico lítico - OOs (Litic Ustifolist); (P2) Chernossolo Háplico Órtico típico - MXo (Typic Haplustoll); (P3) Chernossolo Argilúvico Órtico típico - MTo (Typic Haplustoll); (P4) Gleissolo Melânico Carbonático chernossólico - GMk1 (Typic Epiaquoll); and (P5) Gleissolo Melânico Carbonático organossólico - GMk2 (Terric Haplosaprist). The color of all studied profiles was dark in the surface horizons, and reddish or grayish in deeper layers, according to the drainage conditions. Base saturation was high in all layers, with calcium as dominant cation in the exchangeable complex. Humin was the dominant organic carbon fraction of the studied soils. A mineralogical analysis showed the presence of calcite in the sand fraction in the soil profiles GMK1 and GMk2 and kaolinite, illite and montmorillonite in the clay fraction of all soils. The occurrence of Ustifolist in non-mountainous environments, different from the characterization by the SiBCS, suggests a greater range of possible environmental conditions for the occurrence of this suborder.


News Article | February 22, 2017
Site: co.newswire.com

The US country boasts some of the top universities in the world, making it a destination of choice when studying internationally. American universities have seen a 40% increase in the number of international students choosing to study in the US. In 2016, the international student population exceeded one million. These students come from all over the world to study various majors, ranging from STEM majors to business majors. They will be making America their home, at least until they graduate. After graduating, however, international students only have 60 days before they must return back to their home country. If they wish to gain some work experience in the US they can with Optional Practical Training (OPT), a 12-month working period granted to F-1 students. Students can complete OPT either before graduation or after. In order to apply to OPT, students must have completed nine or more months of education at a US university. They only have a total of 12 authorized months that they can complete. Students can apply for OPT up to 90 days prior to graduating for a post-graduation OPT. There are several steps and a lot of paperwork to fill out when applying for OPT, all of which takes time. Students submit OPT applications to their schools International Student Services office. This process can take 1-2 weeks. After the students receive their documents and OPT package, they need to fill out the forms and ship the documents to the United States Citizenship and Immigration Services (USCIS) office. Students are recommended to start the OPT process early because it can take the USCIS several months to process the application. There are only two USCIS locations that accept OPT applications: Phoenix and Dallas. The state the student resides in will determine which location they will send the paperwork to. Because time is sensitive, students may want to consider expediting the process. eShipGlobal’s University Express Mail Service (UEMS), a trusted shipping service used by over 800 universities, has recently updated their system to making it even easier to ship OPT applications. The UEMS system is completely free to sign up and the process is simple. Once signed in they click the OPT/Send to USCIS option and follow the steps. The USCIS addresses are already loaded into the system, so students just need to select the location they need to send their OPT to. Students can ship using trusted shipping carriers like UPS and FedEx, while saving money through the use of eShipGlobal’s discounted shipping rates. There is only a 150-day time frame in which students have to complete the OPT process. UEMS’s new streamlined process for shipping OPT applications hopes to help students save not only money but also time. eShipGlobal is dedicated to serving the global community by providing solutions that simplify and enhance the shipment of goods. Their software shipping solutions make it easier for universities, research labs, and businesses to better manage their shipping while saving time and money.

Loading UEMS collaborators
Loading UEMS collaborators